MedPoint Clinical Research - Nashville Dashboard
Site performance overview
ACTIVE TRIALS
4
3G / 1A / 0R
ENROLLMENT
63%
297 / 470 patients
FTE UTILIZATION
85%
10.2 / 12 FTE allocated
SITE RISKS
2
Require attention
AVG ENROLLMENT RATE
74.3
patients/month/trial
SITE BUDGET
$0.0M
Across 4 trials
SITE CAPACITY
12 FTE
6 concurrent trials
OPPORTUNITIES
3
Pending review
Active Trials at MedPoint Clinical Research - Nashville
APEX-301
PHASE III
Advanced Non-Small Cell Lung Cancer
Apex Therapeutics • Oncology
ENROLLMENT
125 / 180
69%
SITE BUDGET
$NaNK
FTE ALLOCATED
FTE
CARDIO-SHIELD-2
PHASE II
Heart Failure with Reduced Ejection Fraction
HeartBio Sciences • Cardiology
ENROLLMENT
78 / 100
78%
SITE BUDGET
$NaNK
FTE ALLOCATED
FTE
NEURO-PATH-7
PHASE III
Alzheimer's Disease
NeuroScience Corp • Neurology
ENROLLMENT
68 / 150
45%
SITE BUDGET
$NaNK
FTE ALLOCATED
FTE
ONCO-BRIDGE-9
PHASE I
Advanced Solid Tumors
Bridgeway Oncology • Oncology
ENROLLMENT
26 / 40
65%
SITE BUDGET
$NaNK
FTE ALLOCATED
FTE
SITE RISKS
20
Screen failure rate significantly above benchmark
ENROLLMENT • Dr. Sarah Chen
16
Budget overrun due to extended enrollment period
BUDGET • Finance Team
FTE ALLOCATION
Total Capacity
12 FTE
Allocated
10.2 FTE
Available
1.8 FTE
85% utilized
QUICK ACTIONS